Looks like you’re on the UK site. Choose another location to see content specific to your location
Siemens Healthineers acquires NEO New Oncology
Siemens Healthineers has announced the acquisition of NEO New Oncology in a move that will help to expand the scope of its diagnostics portfolio.
The acquisition will provide Siemens Healthineers with the capability to offer molecular testing-related services and technologies for oncology and genomics for the first time.
NEO New Oncology's cancer genome diagnostic platform NEO provides comprehensive molecular information to help select targeted cancer therapies, while the company is also developing molecular profiling assays based on next-generation sequencing for tissue specimens and body liquids.
Established in 2012, the business has almost 30 employees and is headquartered in Cologne.
Sebastian Kronmueller, head of molecular services at Siemens Healthineers, said: "We are already working with the NEO New Oncology team and strong partners in research to further broaden our molecular services portfolio."
This comes after Siemens rebranded its healthcare division under the new name Siemens Healthineers earlier this month.
We currently have 6 jobs available in Pharmacy industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard